The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'm gonna tell them to stop your cocoa if you keep nodding off Fruits.
Mr Costs
The positives are thin pickings but:
There will be another respiratory virus outbreak and governments and the private sector have that in their sights
Early intervention with IFN in an outbreak- say an old people’s home - could be useful.
If some efficacy can properly be demonstrated then this product might have a commercial future as an extra tool in the physicians tool box.
The share price is reasonably cheap
The final possibility is that the research on bio markers or the interaction with viruses and IFN suppression gives new insight as to how IFN may be used strategically . But that is speculative at the moment.
What seems really unlikely is that this will become the blockbuster some think it will.
I repeat people have been saying IFN will revolutionise therapy since the 1970s.
Given where we are and the cash spend I doubt the company will survive but it might
The spread here is fecking a joke for penny share
Hear hear DocD and T-P,
We all await illumination on the strategy by the company and I have zero to add, other than hoping that all us LTI’s will eventually get some meaningful results 🤪🤔🙏
MrCosts.
LTIs, like myself, are the wrong people to seek advice from. I have made the same error as yourself, in holding too much stock prior to the P3 trial outcome in Feb 2022. Further, in retrospect, I should have sold out and invested elsewhere when TFG Holdings added to their stake resulting in the only share price rise with an underlying cause in over two years.
Doc.Daneeka has provided a good summary of the last two years from an LTI's perspective. To summarise, after all this time, we are still waiting for a detailed announcement from Synairgen to launch their strategy. This needs to happen soon owing to the company's diminishing cash reserves. I am reading Spacman's contributions with interest. However, like all LTIs, my hopes are pinned on, hopefully, imminent news from the company concerning the P2 trials. For sure, they have not endeared themselves to LTIs by not issuing any updates for so long.
GLALTIs.
What company was that Aether?
Doc.Dan - Yes, that sums it up.
The company I was originally going to invest in subsequently increased four fold.
In normal circumstances, I don't think I would have invested in this company.
" I have no idea why new investors would want to be 'part' of this company. "
If you were looking at this for the first time with clean eyes, and had done the due diligence, you almost certainly wouldn't invest now, but there'd be a strong asterisk next to SYN for the next RNS which will either set the train back on the tracks or see it trundling into a siding forever. You'd be as interested in the scientific case as we were in 2020 and see a continuing need for what the company might one day be able to offer - but you'd have concerns about the mistakes made and the ability of the leadership team to seal the deal after 20 + years of slow progress, dramatic success and then last fence failure.
Existing shareholders - like Marley's ghost - carry the chains forged over the last 4 years and beyond. We're sticking with it because most of us were pulled in after Magic Monday and don't really know what we're doing in the markets. The cleverest science bods are rank amateurs in stock market terms, whilst the experienced traders who were not emotionally involved accepted the loss and got out as soon as the first bounce came in early 22. Most of us are stuck like MrC with averages in the £s - but unlike MrC who sees nothing but darkness, everyone else - even those of us still critical of the company - see the possibility of redemption. The company wasted the big chance the pandemic brought - but is finally on a track that we all can understand. I mkean we hope it is - as we have had zero information for 7 months . If the money lasts till the P2s are completed Synairgen will still be in the game. It'll surrender plenty of equity to pay for the big P3 to come and get through to authorisation but long suffering pis might still get something back.
Mr cost grow up.
You do have a choice today: buy hold sell short.
I believe you feel stuck so that sound like a : hold
A hold for you today is the same as a buy for a new investor today.
If you really think nothing positive: sell and go on with life and maybe invest in something else or do not invest.
But i am convinced you will do nothing as you are just incapabele of making choices and own them. Good luck
TP - the reason was I remain 'invested' is I am locked into this company following a 97% share price collapse. I have no choice.
I have no idea why new investors would want to be 'part' of this company.
No products
No trials
No communications
No revenue
It also appears the board of directors don't value their shareholders.
Genuinely, help me out if you can. What are the positives?
This will have been written by a PR firm when the
website was re-designed. Naturally they go for a
narrative that suggests we are much more than a
small research company. It may well work on new
investors who have not been on the journey that LTH's have endured.
But I think it has the opposite effect for those of us who have
seen wasted opportunities, broken promises and a distinct
lack of respect for Pi's who have backed the science, paid
the wages and do not even get a 6 monthly update! The
results RNS has never been such a key event for shareholders..
We wait to see what our financial status is, and confirmation
that our trials will start in H1. If not can we rely on our "World-Class"
Partners to come to our rescue.... Words are cheap a lack of
progress will be expensive!
The following bullet points are from the investors’ page on Synairgen’s website.
* Pioneering science.
* Clinical Need - large and growing.
* Experienced leadership team.
* Wholly-owned and novel investigative product.
* World-class partners.
The first two are presumably the primary reasons that LTIs have remained invested throughout the underwhelming post-Sprinter era to date? This is true in my case.
Unfortunately, the combined experience of the leadership team has not been reflected in their actions over the last twenty six months, as many LTIs have pointed out recently.
However, the fourth and fifth points should attract the attention of short term investors. Are these valid, statements or is it yet more hyperbolic language from the company?
Some clarity from the CEO and BOD , especially with regard to the status of the P2 trials is by now long overdue.
All IMHO. GLALTIs.
Great post Spacman. Some on here think trials to start end of Q1 2024 is on target.
The target start date for trials started with the RNS in April 22, then end of 2023 and now end of Q1 2024.
My view based on the silence from the company, considering the above and 97% in share price, trials will be delayed again!
Cave door has to open shortly
Correction - the 2022 Annual Report was signed off by BDO in May 2023 (not 2022 of course). Apologies.
Just gone back and checked - the 2022 Annual Report (that BDO signed off on in May 2022) stated that the P2 trials would commence in H2 2023. It would be interesting to understand what future projections (which underpin the Going Concern assessment) have been provided by the company to BDO for the audit this year, and how much confidence BDO have in those.
It's probably going to take a compliance issue like this to force the BoD's hand to undertake a transaction. Otherwise you've got a "law unto himself" CEO happy to keep taking a £350k package for "leading" an organisation that has no trials to run, no customers to serve, no manufacturing to do, no communications to bother about.. but 30 staff to help out just in case.
You really couldn't make it up.
Gunto - the unknown (to us) is the cost of the trials, and if the company is still pre-revenue come the start of Q2 2026 which is what your scenario is suggesting, then all that will be affecting the auditors' confidence in the Going Concern stress-testing they're doing. Do you think BDO have great confidence in the BoD? I doubt it.
Mr Costs - you're right, they could announce cessation of trials intent and then that is a Business Plan (if that's what you can still call it) they can certainly deliver on. But that decision (which would need to be RNS'd as it's a material change in a company that then becomes dormant save for paying salaries) is a game-changer in itself... suddenly the company is saying there are no prospects for ever creating a revenue stream. I'm not a company law expert, but a basic understanding of fiduciary duty would suggest that the directors are then duty-bound to put the company or its assets up for sale to realise value for the shareholders.
AIMHO. DYOR.
Says the Fruit and Veg Market Trader trying to be Mr Wall Street lol. Any one who spu**s 3000 posts on Synairgen in 2 years and rabbits on like you do deserves a Comedy Bafta award to be fair :).
It just got better...........
Comedy duo Mr Tumble and Mr Weed. Could it get any better?
£900 highest trade for world best kept secret.
Silence is golden
What all 31 one of them you nugget! lol....... Fruit Bat at it again! Evil Knievel could of done with your Ramps when he was trying to jump the Grand Canyon lol.
Looking at today's trades, it looks like tumble weed is in demand today! Who would have guessed.
............ ! That is all that can be discussed on here! As nothing else apart from a vastly reduced financial position over past 26 months!
Doc83.
The fact that shareholders, who care about the company and its future, requested more frequent feedback at the last AGM is significant.
Synairgen’s total disregard of a perfectly reasonable request speaks volumes about the arrogance of the CEO and BOD. I have no evidence, as such, but have long suspected that the company isn’t as well led as it ought to be? Obfuscation through a refusal to communicate is a means of covering up any lack of competence in the actions of the leadership group.
We will know soon enough, and can but hope that my thoughts turn out to be entirely misplaced, and that the company actually delivers appropriate P2 trials, as previously specified.
GLALTIs.